Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The PART study is a feasibility study comparing partial ablation (PA) and radical prostatectomy (RP) in men with intermediate risk unilateral prostate cancer. The aim of the feasibility is to determine whether or not it is possible to recruit and randomise men to a trial of this nature.

The PART Trial is a multicentre randomised controlled (RCT) trial funded by the NIHR HTA, and run out of SITU in Oxford. The Chief Investigator is Professor Freddie Hamdy, and the Trial Manager is Steffi le Conte.

Aims

The PART study aims to assess the clinical effectiveness and cost-utility of partial ablation (using HIFU) or radical prostatectomy in patients with intermediate risk, unilateral clinically localised prostate cancer. Phase 1 of the PART study aims to explore the methods and feasibility of data capture instruments.

 

Background

Over decades, the principle of surgical ablation and/or radical treatment for cancer has evolved from total and extensive treatment of the affected organs to a more targeted and focal approach with, apparently, equal if not superior effectiveness, as well as fewer adverse events and improved quality of life. The concept is now evolving in prostate cancer using the promising but largely untested emerging technologies described above. Rather than radical therapy treating the whole gland, the aim is to localise and treat the main focus of cancer. An RCT is therefore needed to compare the effectiveness of this newer treatment, compared to the current gold standard treatment, radical prostatectomy. 

Our team